Capital International Investors Has $85.33 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Capital International Investors lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 92.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,361,746 shares of the company's stock after buying an additional 1,136,079 shares during the period. Capital International Investors owned about 3.17% of SpringWorks Therapeutics worth $85,330,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Huntington National Bank increased its position in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after purchasing an additional 192 shares during the last quarter. AlphaQuest LLC raised its holdings in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new position in SpringWorks Therapeutics during the fourth quarter worth approximately $45,000. KBC Group NV increased its holdings in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after acquiring an additional 978 shares during the last quarter. Finally, US Bancorp DE raised its stake in SpringWorks Therapeutics by 56.0% in the 4th quarter. US Bancorp DE now owns 4,336 shares of the company's stock valued at $157,000 after acquiring an additional 1,556 shares during the period.

Insider Buying and Selling at SpringWorks Therapeutics

In related news, insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total transaction of $62,169.04. Following the sale, the insider now owns 62,053 shares in the company, valued at $3,797,023.07. The trade was a 1.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the completion of the transaction, the chief operating officer now owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. This trade represents a 10.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,766 shares of company stock worth $24,402,956 over the last 90 days. Insiders own 7.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on SWTX. Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Evercore ISI raised their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Finally, Wedbush reissued an "outperform" rating and set a $81.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $73.20.

SpringWorks Therapeutics Trading Up 9.0 %

NASDAQ SWTX traded up $3.72 during trading on Thursday, reaching $44.93. The company's stock had a trading volume of 8,811,959 shares, compared to its average volume of 1,435,986. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of -12.91 and a beta of 0.79. The firm has a 50 day moving average price of $46.68 and a 200 day moving average price of $40.33. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. On average, equities analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.